Genisphere Develops a Universal Signal Amplification Process for Lateral Flow Rapid Test Applications

HATFIELD, Pa., Oct. 7, 2013 /PRNewswire/ -- Genisphere LLC reported today it has adapted its 3DNA^® Nanotechnology for use as a universal signal amplification system for improving the sensitivity and overall performance of rapid diagnostic tests and applications. Detailed in a patent application submitted on August 16^th, the new process is a further enhancement of the 3DNA^® Signal Amplification technology, and eliminates the need for custom chemical modification of antibodies when combined with 3DNA^® signal amplifiers and used as detection reagents in lateral flow rapid immunoassays. 

"It's well known that sensitivity is a major driver of commercial success and value for point-of-care tests," said Jim Kadushin, Genisphere's Chief Operating Officer. "Genisphere's new process for combining analyte-specific antibodies with 3DNA^® signal amplifiers will streamline the development of more sensitive tests and reduce costs to address the highly competitive rapid diagnostics market."

Genisphere's 3DNA^® Nanotechnology has been used to improve the performance of a variety of assay platforms for protein and nucleic acid detection, including microarrays, ELISAs, bead-based flow cytometry, and most recently, lateral flow rapid tests. The 3DNA^® reagent provides up to 100-fold improvement in sensitivity without increasing the assay's complexity. This improved performance enables point-of-care analyses that have not previously been possible with conventional systems.

"Genisphere is partnering with key successful players in fast growing markets," said Bob Getts, Genisphere's Chief Science Officer. "We believe our new proprietary process provides more flexibility and a faster-to-market path for companies interested in collaborating with Genisphere to improve the performance of their existing products or assays still in the R&D pipeline."

About Genisphere
Genisphere LLC is a nanotechnology company providing innovative tools for targeted drug delivery, clinical diagnostics and life science research based on the company's 3DNA nanoparticle platform. Genisphere's unique, IP-protected, 3DNA^® technology has broad applicability to improve the sensitivity in immunoassay and nucleic acid detection platforms, as well as to deliver therapeutics in a highly specific manner. Genisphere has successfully out-licensed several reagent kits to the research market, and provides customized products to improve the limit of detection of high-sensitivity lateral flow point-of-care tests, enabling their commercialization. Genisphere's diagnostic partners have a competitive advantage due to 3DNA's ability to improve their test's sensitivity, with minimal additional costs and no alterations to end-user protocols. For targeted therapeutics, Genisphere provides a fully customizable all-DNA drug delivery platform. Genisphere's robust nanocarrier delivers small drug, RNAi and gene construct therapeutics with greatly improved efficacy and reduced toxicity. The company is continuing to seek partnerships with biotechnology and pharmaceutical companies that could benefit from Genisphere's platform technology. For more information, please visit www.genisphere.com

For more information contact:

Jim Kadushin
Genisphere
215-996-3027
Email

Read more news from Genisphere.

SOURCE Genisphere